Adherence monitoring methods to measure virological failure in people living with HIV on long-term antiretroviral therapy in Uganda
Authors:
- Stephen OkoboiSOStephen Okoboi
- Joseph MusaaziJMJoseph Musaazi
- Rachel KingRKRachel King
- Sheri A LippmanSLSheri A Lippman
- Andrew KambuguAKAndrew Kambugu
- Andrew MujugiraAMAndrew Mujugira
- Jonathan IzudiJIJonathan Izudi
- Rosalind Parkes-RatanshiRPRosalind Parkes-Ratanshi
- Agnes N KiraggaAKAgnes N Kiragga
- Barbara CastelnuovoBCBarbara Castelnuovo
Open Access
- 30 December 2022
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS Global Public Health
- Vol. 2 (12) , e0000569
Abstract
Appointment keeping and self-report within 7-day or and 30-days recall periods are non-objective measures of antiretroviral treatment (ART) adherence. We assessed incidence of virological failure (VF), predictive performance and associations of these adherence measures with VF among adults on long-term ART. Data for persons initiated on ART between April 2004 and April 2005, enrolled in a long-term ART cohort at 10-years on ART (baseline) and followed until December 2021 was analyzed. VF was defined as two consecutives viral loads ≥1000 copies/ml at least within 3-months after enhanced adherence counselling. We estimated VF incidence using Kaplan-Meier and Cox-proportional hazards regression for associations between each adherence measure (analyzed as time-dependent annual values) and VF. The predictive performance of appointment keeping and self-reporting for identifying VF was assessed using receiver operating characteristic curves and reported as area under the curve (AUC). We included 900 of 1,000 participants without VF at baseline: median age was 47 years (Interquartile range: 41–51), 60% were women and 88% were virally suppressed. ART adherence was ≥95% for all three adherence measures. Twenty-one VF cases were observed with an incidence rate of 4.37 per 1000 person-years and incidence risk of 2.4% (95% CI: 1.6%-3.7%) over the 5-years of follow-up. Only 30-day self-report measure was associated with lower risk of VF, adjusted hazard ratio (aHR) = 0.14, 95% CI:0.05–0.37). Baseline CD4 count ≥200cells/ml was associated with lower VF for all adherence measures. The 30-day self-report measure demonstrated the highest predictive performance for VF (AUC = 0.751) compared to appointment keeping (AUC = 0.674), and 7-day self-report (AUC = 0.687). The incidence of virological failure in this study cohort was low. Whilst 30- day self-report was predictive, appointment keeping and 7-day self-reported adherence measures had low predictive performance in identifying VF. Viral load monitoring remains the gold standard for adherence monitoring and confirming HIV treatment response.Keywords
All Related Versions
Funding Information
- Fogarty International Center of the National Institutes of Health (Award Number D43TW009343)
This publication has 22 references indexed in Scilit:
- A Single Quantifiable Viral Load Is Predictive of Virological Failure in Human Immunodeficiency Virus (HIV)-Infected Patients on Combination Antiretroviral Therapy: The Austrian HIV Cohort StudyOpen Forum Infectious Diseases, 2016
- Outcomes in a Cohort of Patients Started on Antiretroviral Treatment and Followed up for a Decade in an Urban Clinic in UgandaPLOS ONE, 2015
- Community-based ART distribution system can effectively facilitate long-term program retention and low-rates of death and virologic failure in rural UgandaAIDS Research and Therapy, 2015
- Factors Influencing Antiretroviral Adherence and Virological Outcomes in People Living with HIV in the Highlands of Papua New GuineaPLOS ONE, 2015
- High Level of Virological Suppression among HIV-Infected Adults Receiving Combination Antiretroviral Therapy in Addis Ababa, EthiopiaAntiviral Therapy, 2015
- Self-Report Measures in the Assessment of Antiretroviral Medication AdherenceJournal of the International Association of Providers of AIDS Care (JIAPAC), 2014
- Pharmacy refill adherence outperforms self-reported methods in predicting HIV therapy outcome in resource-limited settingsBMC Public Health, 2014
- Plasma HIV-1 RNA Detection Below 50 Copies/mL and Risk of Virologic Rebound in Patients Receiving Highly Active Antiretroviral TherapyClinical Infectious Diseases, 2012
- HIV-1 viral load testing cost in developing countries: what’s new?Expert Review of Molecular Diagnostics, 2007
- Optimal Recall Period and Response Task for Self-Reported HIV Medication AdherenceAIDS and Behavior, 2007